Oncolytic adenovirus Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123, igrelimogene litadenorepvec) shows promise as a therapeutic agent capable of causing tumor regression and activating host immunity. A phase 1 clinical study TUNIMO (NCT04695327) assessed its safety as monotherapy in patients with various ...
ORGANISM(S): Homo sapiens